Question 1

How does reserpine affect catecholamine levels in adrenergic neurons?

Accepted Answer

Reserpine blocks the vesicular monoamine transporter (VMAT), preventing catecholamines from entering synaptic vesicles. This causes catecholamines to accumulate in the cytosol, where they are degraded by the enzyme MAO. The result is reduced sympathetic transmission because fewer neurotransmitters are available for release at the synapse.

Question 2

What is the mechanism of action of guanethidine as a sympatholytic agent?

Accepted Answer

Guanethidine enters nerve endings and accumulates in synaptic vesicles, where it displaces noradrenaline. This impedes vesicular exocytosis and prevents neurotransmitter release at the synapse, blocking impulse conduction. At higher doses, guanethidine can also cause structural damage to neurons, further reducing sympathetic activity.

Question 3

Why do noradrenaline reuptake inhibitors increase sympathetic activity?

Accepted Answer

Noradrenaline reuptake inhibitors block the norepinephrine transporter, preventing catecholamines from being removed from the synaptic space. This allows noradrenaline to remain active longer and continue stimulating adrenergic receptors. Drugs like cocaine enhance sympathetic activity through this mechanism by obstructing catecholamine reuptake.

Question 4

What classes of drugs inhibit the norepinephrine transporter?

Accepted Answer

Serotonin-noradrenaline reuptake inhibitors like duloxetine, tricyclic antidepressants like imipramine, and indirect-acting agonists like cocaine all inhibit the norepinephrine transporter. These drugs prevent the reuptake of catecholamines from the synaptic space, prolonging their effects on adrenergic receptors and enhancing sympathetic transmission.

Question 5

Why have older catecholamine-affecting drugs been replaced in clinical practice?

Accepted Answer

Drugs like reserpine, guanethidine, tricyclic antidepressants, and cocaine have significant side effects that limit their therapeutic use. Newer, more selective agents have been developed that target specific pathways with fewer adverse effects. Understanding these older drugs remains important for comprehending how catecholamine release and reuptake mechanisms work in treating various disorders.

Question 6

How do reserpine and guanethidine differ in their effects on neurotransmitter release?

Accepted Answer

Reserpine blocks catecholamine storage by inhibiting the vesicular monoamine transporter, leading to cytosolic degradation. Guanethidine directly displaces noradrenaline from vesicles and impedes exocytosis. While both reduce sympathetic transmission, reserpine acts on storage mechanisms, whereas guanethidine physically disrupts vesicular release and can cause neuronal damage at higher doses.

Question 7

What happens to catecholamines when they accumulate in the neuronal cytosol?

Accepted Answer

When catecholamines accumulate in the cytosol due to blocked vesicular uptake, they become susceptible to degradation by monoamine oxidase (MAO). This enzymatic breakdown reduces the amount of functional neurotransmitter available for synaptic release, ultimately decreasing sympathetic transmission and adrenergic signaling throughout the body.

Fármacos que afectan la liberación o captación de neurotransmisores

Browse More Videos